Results for this period
Full year1 April 2025–31 March 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Net sales increased due to the expansion of workplace sales, the launch of new products, a review of selling prices, and stronger advertising and promotional activities in Indonesia. Profit declined due to investments in human resources, higher advertising expenses, higher raw material costs resulting from the surge in platinum prices, and start-up costs for the healthcare-related business, among other factors.
Not applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | ¥24,159 million (YoY +7.5%) |
| Operating profit | ¥2,940 million (YoY -10.5%) |
| Ordinary income | ¥3,147 million (YoY -11.0%) |
| Profit attributable to owners of the parent | ¥2,030 million (YoY -9.4%) |
| Net income per share | ¥269.58 |
| Operating Margin | 12.2% |
| Equity ratio | End of the current fiscal period 65.8% / End of previous period 67.8% |
| Total assets | ¥36,067 million |
| Net assets | ¥25,481 million |
| Cash flows from operating activities | ¥2,851 million |
| Cash flows from investing activities | ¥-2,074 million |
| Cash flows from financing activities | ¥-2,411 million |
| Cash and cash equivalents at end of period | ¥13,709 million |
| Full-year earnings forecast | Net Sales ¥27,000 million (YoY +11.8%) / Operating profit ¥3,300 million (YoY +12.2%) / Ordinary income ¥3,500 million (YoY +11.2%) / Net income ¥2,200 million (YoY +8.3%) |
| Annual Dividend Forecast | ¥130 → ¥130（0.0%） |
| Payout ratio | 48.2% |
| Shareholder Return Policy | The company aims for ROE of at least 10% as a target metric and plans to pay progressive dividends based on a DOE of 4% while maintaining financial soundness. The company recognizes its cost of capital as being approximately 8%. |
| Segment revenue | Water Healthcare Business ¥21,135 million (YoY +8.0%), Medical-related business ¥3,024 million (YoY +4.4%) |
| Segment profit | Water Healthcare Business ¥2,711 million (YoY -6.4%), Medical-related business ¥228 million (YoY -41.3%) |
| Depreciation and amortization | ¥512,546 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥961 thousand / Extraordinary loss Loss on Disposal of Fixed Assets ¥1,751 thousand |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 companies (none applicable) / Excluded 0 companies (none applicable) |
| Material subsequent events | Not applicable. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for institutional investors) |
| Issued Shares at Period-End | 8,656,780 |
| Treasury Shares at Period-End | 1,222,590 |
| Factors Behind Changes in Business Performance | Net sales increased due to the expansion of workplace sales, the launch of new products, a review of selling prices, and stronger advertising and promotional activities in Indonesia. Profit declined due to investments in human resources, higher advertising expenses, higher raw material costs resulting from the surge in platinum prices, and start-up costs for the healthcare-related business, among other factors. |
Items this document does not state (4)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Net sales increased due to the expansion of workplace sales, the launch of new products, a review of selling prices, and stronger advertising and promotional activities in Indonesia. On the profit front, results were affected by increased investment in human resources, higher advertising expenses in Indonesia, and higher raw material costs resulting from a surge in platinum prices used for electrode plates, as well as investment in human resources, the restructuring of the sales organization, and start-up costs for the Singapore business in the healthcare-related business.